|
流感病毒传染性NYMCX-387[A/马里兰/02/2021][H3N2]23/134
|
EA
|
23/134
|
咨询
|
1-4/12周
|
|
流感病毒传染性NYMCX-393[A/西弗吉尼亚州/30/2022][H1N1]23/152
|
EA
|
23/152
|
咨询
|
1-4/12周
|
|
流感病毒传染性NYMCX-391A[A/贵州-柳枝特/326/2021][H3N2]23/138
|
EA
|
23/138
|
咨询
|
1-4/12周
|
|
流感病毒传染性NYMCX-391[A/贵州-柳海特/326/2021][H3N2]23/136
|
EA
|
23/136
|
咨询
|
1-4/12周
|
|
抗脑膜炎球菌人类参考血清B组23/142
|
EA
|
23/142
|
4502
|
1-4/12周
|
|
流感病毒传染性SAN-019[A/Alaska/01/2021][H3N2]23/118
|
EA
|
23/118
|
咨询
|
1-4/12周
|
|
甲型流感病毒传染性/西弗吉尼亚州/30/2022[H1N1]23/122
|
EA
|
23/122
|
咨询
|
1-4/12周
|
|
流感病毒传染性NIB-134[A/加泰罗尼亚/NSVH161512065/2022[H1N1]23/126
|
EA
|
23/126
|
咨询
|
1-4/12周
|
|
流感病毒传染性NYMCBX-117[B/浙江-南湖/1854/2021][B-维多利亚谱系]23/132
|
EA
|
23/132
|
咨询
|
1-4/12周
|
|
流感病毒传染性SAN-018[A/马里兰/02/2021][H3N2]23/116
|
EA
|
23/116
|
咨询
|
1-4/12周
|
|
流感病毒传染性A/威斯康星州/67/2022[H1N1]23/120
|
EA
|
23/120
|
咨询
|
1-4/12周
|
|
流感抗A/Victoria/4897/2022样[H1N1]HA血清23/100
|
EA
|
23/100
|
4081
|
1-4/12周
|
|
流感抗原A/维多利亚/4897/2022[IVR-238][H1N1]22/320
|
EA
|
22/320
|
4081
|
1-4/12周
|
|
世界卫生组织絮凝试验用白喉抗毒素国际参考试剂[马]23/102
|
EA
|
23/102
|
4988
|
1-4/12周
|
|
流感病毒传染性NIB-133[A/Norway/31694/2022][H1N1]23/112
|
EA
|
23/112
|
咨询
|
1-4/12周
|
|
流感病毒传染性SAN-010[A/Darwin/09/2021][H3N2]23/114
|
EA
|
23/114
|
咨询
|
1-4/12周
|
|
甲基化人血清白蛋白[mHSA]23/106
|
EA
|
23/106
|
4502
|
1-4/12周
|
|
抗肺炎球菌血清型35B单克隆抗体[克隆3F9]22/308
|
EA
|
22/308
|
2883
|
1-4/12周
|
|
流感病毒传染性A/维多利亚/4897/2022[H1N1]22/316
|
EA
|
22/316
|
咨询
|
1-4/12周
|
|
抗肺炎球菌血清型22F单克隆抗体[克隆17-122JB11IB11]22/306
|
EA
|
22/306
|
2883
|
1-4/12周
|
